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tisements increased awareness of new treatment (perceived
beneﬁt) and improved discussion with health professionals (per-
ceived beneﬁt) were both positively associated with switching
request (p = 0.001 and p < 0.0001, respectively). Believing that
DTC advertisements led to decreased conﬁdence in doctor’s judg-
ment (perceived barrier) was negatively associated with switch-
ing request (p = 0.02). Patients on regular medication (OR, 
2.03; 95% CI, 1.48–2.78), black patients (OR, 2.76; 95% CI,
1.48–5.13), patients with higher attentiveness to DTC advertis-
ing (p < 0.0001), and patients with allergies (OR, 1.35; 95% CI,
1.01–1.79), asthma (OR, 1.71; 95% CI, 1.09–4.33), or anxiety
(OR, 1.60; 95% CI, 1.23–2.57), were more likely to make
switching requests. CONCLUSIONS: Patients’ switching
requests were associated with health beliefs, race, health status,
and attentiveness to DTC advertising.
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OBJECTIVES: To investigate the prevalence of potentially inap-
propriate medication prescribing (PIP) among elderly residents
in Regione Emilia Romagna (RER), Italy and to examine factors
associated with having PIP. METHODS: We conducted a retro-
spective cohort study using the 2001 outpatient prescription
claims RER database. We linked individuals in this database with
information (age, gender, and other variables) available from a
demographic ﬁle of approximately 1 million elderly RER resi-
dents. The cohort comprised 849,425 subjects 65 years or older,
who had at least one drug prescription during the study period.
PIP was deﬁned as having a prescription claim for a medication
included in the 2003 Beers updated list of drugs to be avoided
in the elderly. Of the 48 medications in the list, 19 were reim-
bursed in 2001 by the Italian National Formulary and included
in the analysis. RESULTS: A total of 152,641 elderly in the
cohort (18.0%) had 1 or more occurrences of PIP. Of these,
11.5% received prescriptions for 2 medications of concern and
1.7% for 3 or more. Doxazosin (23.0% of the subjects) was the
most frequently occurring PIP, followed by ketorolac (20.5%),
ticlopidine (18.3%), and amiodarone (12.6%). More than half
of the PIP was for drugs with the potential for severe adverse
outcomes. Factors associated with greater likelihood of PIP were
male, older age, overall number of drugs prescribed, greater
number of chronic conditions, and lower income level. CON-
CLUSIONS: This study provides strong evidence that PIP for
elderly ambulatory patients is a substantial problem in Italy.
Because we were able to analyze only a fraction of the Beers’
drugs list, our results underestimate the extent of PIP. The aware-
ness of the prevalence of PIP and associated determinants may
be useful in designing and implementing effective programs 
targeting outpatient practitioners to inﬂuence their prescribing
behavior to reduce PIP.
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OBJECTIVES: To analyze the comparative cost effectiveness of
epoetin alfa (EPO) and darbepoetin alfa (DARB) based on the
FDA-approved doses for EPO (40,000 Units/week) and DARB
(2.25mcg/kg/week) for the treatment of chemotherapy-induced
anemia (CIA). METHODS: Clinical results were drawn from
two randomized, double blind, placebo-controlled phase III 
registration trials (EPO, N = 344 patients, JCO Sep 27, 2004
[Epub ahead of print]; DARB N = 320 patients, JNCI 2002
94:1211–20; abstract 981 Eur J Cancer 2001 37, Suppl 6: 264).
Effectiveness was based on the red blood cell transfusion rate
between Week 5 and the end of Week 12 and was standardized
as the difference in transfusion rates between the active drug 
and the respective placebo, divided by the transfusion rate for
the placebo. Estimated costs were presented in 2004 USD and
included drug, physician services, transfusions, laboratory, and
patient opportunity costs. Cost-effectiveness was calculated as
average cost divided by transfusion effectiveness. Threshold
analysis was conducted by ﬁnding the break even point at which
EPO and DARB have the same total cost and cost-effectiveness
ratio, respectively. RESULTS: Estimated total cost over 12 weeks
was $7,618 for EPO and $10,857 for DARB, with drug cost rep-
resenting 85% and 89% for EPO and DARB, respectively. Rel-
ative to placebo, the standardized transfusion effectiveness was
65% for EPO and 48% for DARB, resulting in an average cost
effectiveness ratio of $117 for EPO and $226 for DARB. A 33%
(or 54%) reduction in DARB dose or price would be needed to
equalize the total cost (or cost-effectiveness ratio) with that of
EPO. CONCLUSIONS: Drug cost was determined to be the key
driver of total cost. In addition, this analysis found EPO to be
more effective in reducing blood transfusion requirements and
less costly, and hence the dominant alternative compared to
DARB for the treatment of CIA.
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OBJECTIVES: To determine the value-for-money offered by
pemetrexed (Alimta) plus cisplatin therapy for patients with
malignant pleural mesothelioma (MPM), relative to cisplatin
monotherapy, in Australia. MPM is an uncommon, locally inva-
sive and rapidly fatal malignancy. There is currently no other
drug reimbursed by the Australian National Formulary speciﬁ-
cally for the treatment of mesothelioma. METHODS: A 
comprehensive literature search revealed one randomised head-
to-head trial of pemetrexed plus cisplatin therapy versus cisplatin
monotherapy (N = 448), by Vogelzang et al. (2003). Median 
survival for the intention-to-treat (ITT) population was 12.1
months for the pemetrexed plus cisplatin arm versus 9.3 months
for the cisplatin arm (hazard ratio = 0.77, p = 0.020). Although
there was greater toxicity with the combination regimen, quality
of life was not negatively impacted. Mean survival time for each
treatment arm was estimated from Kaplan-Meier survival curves.
Resource use was applied as per the trial and costed accordingly.
Study drug utilisation, concomitant medications, supplementary
medication (dexamethasone, folic acid, and vitamin B12), post-
study chemotherapy, and care for serious and treatment-emer-
gent adverse events were costed. RESULTS: Patients received a
mean of 4.7 treatment cycles in the pemetrexed plus cisplatin
arm, and 4.0 cycles in the cisplatin monotherapy arm. The com-
bination therapy required more supportive care for toxicities.
